DAYBU nears EU green light, unlocking US$35m upfront for Neuren Pharmaceuticals
Neuren Pharmaceuticals (ASX:NEU) says the European Medicines Agency’s CHMP has adopted a positive opinion, after re‑examination, recommending the European Commission grant marketing authorisation for DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and children aged five and over.










